Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 Operating Margin % is 0.34% as of Jun. 2026. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Mentice AB ranks worse than 56.07% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Mentice AB's Operating Income for the
three
months ended in Jun. 2026 was €0.03 Mil. Mentice AB's Revenue for the
three
months ended in Jun. 2026 was €7.26 Mil. Therefore, Mentice AB's Operating Margin % for the quarter that ended in Jun. 2026 was 0.34%.
Good Sign:
Mentice AB operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Mentice AB's Operating Margin % or its related term are showing as below:
FRA:MN2'
s Operating Margin % Range Over the Past 10 Years
Min: -22.97 Med: -11.26 Max: 4.71
Current: -0.14
FRA:MN2's Operating Margin % is ranked worse than 56.07% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 3.29
vs FRA:MN2: -0.14
Mentice AB's 5-Year Average Operating Margin % Growth Rate was 26.60% per year.
Mentice AB's Operating Income for the
three
months ended in Jun. 2026 was €0.03 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.05 Mil.
Mentice AB (FRA:MN2) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Mentice AB Operating Margin % Related Terms
Mentice AB Operating Margin % Historical Data
* Premium members only.
The historical data trend for Mentice AB's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MN2 vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, Mentice AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Mentice AB's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Mentice AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a Operating Margin % of 0.34% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Mentice AB and its competitors. According to the industry distribution chart, Mentice AB ranks #457 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is Mentice AB's Operating Margin % too high?
Mentice AB's current Operating Margin % is 0.34%. The Medical Devices & Instruments industry median Operating Margin % is 3.29. Mentice AB's value of 0.34% is 89.7% below this industry median. Based on the distribution chart, Mentice AB ranks #457 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #457 out of 815 companies for Operating Margin %. This places Mentice AB in the lower half of its industry. The industry median Operating Margin % is 3.29. Mentice AB's value of 0.34% is 89.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.29, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Operating Margin % of 0.34% is 89.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Operating Margin % is 0.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current Operating Margin % is 0.34% and 89.7% below the Medical Devices & Instruments industry median of 3.29. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Operating Margin % is 0.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
Operating Margin %: 0.34%
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
Industry Position: 89.7% below the Medical Devices & Instruments median (#457 of 815)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
